Clinical trials

85

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

VR-Cognitive Behavioral Therapy Prehabilitation for Spinal Deformity Surgery

The goal of this clinical trial is to learn whether a virtual reality-based cognitive behavioral therapy (VR-CBT) prehabilitation program can improve recovery and quality of life for adults undergoing elective spine surgery. The main questions it aims to answer are: Does participating in an 8-week VR-CBT prehabilitation program before surgery improve physical function and pain-related outcomes at 12 months after surgery? Does VR-CBT prehabilitation reduce postoperative anxiety, depression, and pain interference compared with usual preoperative care? Researchers will compare participants who receive the VR-CBT prehabilitation program plus usual care to participants who receive usual preoperative care alone to see if the VR-CBT program leads to better recovery and patient-reported outcomes. Participants will: Use a VR headset at home to complete structured CBT-based prehabilitation sessions over 8 weeks before surgery. Attend routine clinic visits and complete questionnaires about pain, function, mood, and quality of life before surgery and through 12 months after surgery. Allow the research team to review their medical records for information about surgery, complications, and postoperative recovery.

Participants needed: 80
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Aug 20, 2026Locations: 2
Eligibility criteria

Adults between 18 and 75 years old.

Neurological conditions that significantly impact cognition or mobility.

Status: Recruiting

Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis

This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.

Participants needed: 20
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Aug 14, 2026Locations: 1
Eligibility criteria

Patients must have a GI tumor [+3]

Status: Recruiting

Using Nicotine to Reverse Age-related Auditory Processing Deficits

The present study will evaluate the effects of both aging and nicotine on psychophysical tasks and electrophysiological measures. Nicotine will be administered to study participants in the form of gum that is available as an over-the-counter medication. The hypothesis is that nicotine will reverse the detrimental effects of aging on auditory processing. The proposed experiments will characterize the effects of nicotine and may eventually lead to improved treatments of hearing loss in a variety of patient populations and in healthy aging.

Participants needed: 48
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Aug 10, 2026Locations: 1
Eligibility criteria

between 18 and 85 years of age [+2]

less than 18 or greater than 85 years of age [+5]

Status: Recruiting

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

Participants needed: 25
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 31, 2026Locations: 1
Eligibility criteria

Age: Subjects must be 18 years of age or older. [+10]

Brain Metastases: Subjects with uncontrolled or symptomatic brain metastases. Su... [+11]

Status: Recruiting

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually. With high-risk human papillomavirus (HR-HPV) as the causative agent for CC, one risk factor that places women at high risk for CC is human immunodeficiency virus (HIV), as impaired immune response against Human papillomavirus (HPV) may result in persistent HR-HPV infection, a critical risk factor for progression of HPV-related cervical oncogenesis. Progression of precancerous lesions among women living with HIV (WLH) is also associated with: 1) lack of HPV screening; 2) high levels of depressive symptoms and stigma; and 3) malnutrition, which negatively impacts the activation and proliferation of immune cells. Yet programs that offer WLH with comprehensive services focused on HPV screening and psychological and nutritional support are almost non-existent, and the gap is critical. Nutrition plays an integral role in relationship to HPV/HIV co-infection, as demonstrated by an increased risk of HR-HPV associated with poor nutrition; nutritional deficiencies are likewise linked to cervical intra-epithelial neoplasia. The immunological effect of malnutrition may also be exacerbated among WLH due to elevated energy demands of chronic immune activation; worsened with HPV/HIV co-infection. Further, depressive symptoms (aka depression for brevity) partially mediate the effect of food insecurity on HIV viral suppression. In our completed ASHA-Nutrition R01 study of antiretroviral (ART) adherence, the investigators trained lay community health peer counselors, named Accredited Social Health Activist (ASHA), to improve the health of 600 rural WLH by providing emotional support, skill-building, nutrition education, and/or protein-enriched food supplements. In that study, our intervention, co-delivered by our trained peer counselors, and guided by nurses, led to increased CD4+ T cell recovery and improved anthropometric and psychosocial outcomes. The investigators found that peer counselors support plus protein supplements and nutritional education were significantly associated with improved CD4 counts and increased lean mass at 18 months (P \< 0.001), as well as significant improvements in depression, ART adherence, social support and internalized stigma. In our sub study, CC screening of 598 of these WLH revealed that 13% were found to have abnormal cervical lesions and 4 (1%) had squamous CC. Preliminary evidence also revealed that nutritional supplements may be associated with a 40% reduction in the risk of abnormal cervical lesions (adjusted odds ratio \[aOR\] = 0.60), with an association between serum albumin and reduced risk of abnormal lesions (aOR= 0.39). With a focus on secondary prevention of CC, the investigators hope to mitigate the link between HR-HPV persistence and risk of CC as well as improve the health of women co-infected with HPV/HIV (W-Co-V). Our stellar team plans to build upon our prior ASHA-Nutrition intervention, using formative research to refine a nurse-led, peer counselors co-delivered, nutrition-enhanced SAKHI HPV intervention, adapted for W-Co-V. This will be followed by a randomized controlled trial (RCT), assessing the efficacy of our refined comprehensive, multifaceted SAKHI HPV intervention, as compared with an enhanced Standard of Care (SOC+) (usual care + 3 sessions \[wellness, basic nutrition and HPV/HIV health promotion\]) among 348 high-risk co-infected women to prevent CC while remaining engaged in the HIV treatment cascade, and managing nutritional health. Recruited participants will be individually randomized in a 1:1 ratio to one of the two study arms. Our Primary outcome is HR-HPV persistence (2 positive tests for the same HR-HPV type, separated by 12-18 months). The two aims incorporating RCT interventions are as follows: Aim 2. To evaluate the efficacy of SAKHI HPV intervention among 348 W-Co-V on the primary outcome (HR-HPV persistence) as compared to the Enhanced Standard of Care (SOC+) program. H2: Compared to the SOC+ participants, SAKHI participants will have lower rates of HR-HPV persistence. Aim 3. Assess the impact of the SAKHI program secondarily on: 1) HIV indices (HIV viral load; CD4 count); 2) Nutritional index (serum albumin) at 6-, 12-, and 18-months.

Participants needed: 348
Trial details
Age: 25-50Biological sex: FemaleType: InterventionalSponsor: University of California, IrvineUpdated: Jul 31, 2026Locations: 4
Eligibility criteria

WLH, 25 - 50 years of age; based on HIV-based guidelines; [+3]

Pregnant or lactating women due to hormonal and dietary guideline differences; [+1]

Status: Not yet recruiting

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screening do not receive it. The purpose of the Empower LCS/Call+ study is to evaluate new strategies to improve lung cancer screening among adults who are eligible for screening based on current U.S. Preventive Services Task Force (USPSTF) guidelines. This pilot randomized controlled trial will enroll approximately 80 participants from UC Irvine Health and Emory Healthcare. Participants will be randomly assigned to receive either enhanced usual care or the Empower LCS/Call+ intervention. The intervention includes educational materials, reminders for patients and primary care providers, and information about financial and community resources when appropriate. Participants who do not complete lung cancer screening after the initial intervention may receive additional telephone-based navigation through the Call+ program to help identify and address barriers to screening and help with scheduling. Participants will complete a baseline survey and follow-up surveys at 4 and 8 months, and researchers will review electronic health record information to determine whether lung cancer screening was discussed, ordered, and completed. Some participants will also be invited to complete a one-time interview about their experiences with the study. The results of this study will help determine the feasibility, acceptability, and preliminary effectiveness of the Empower LCS/Call+ intervention and will inform future efforts to improve equitable access to lung cancer screening.

Participants needed: 80
Trial details
Age: 50-80Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 22, 2026Locations: 57
Eligibility criteria

Must meet current USPSTF eligibility criteria for lung cancer screening (Current... [+4]

Meet the eligibility upper age limit during initial 4-month participation. [+4]

Status: Recruiting

An Acupuncture Study for People At High Risk for Sepsis

Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham acupuncture is performed the same way as real acupuncture but will use different needles and target different sites or places on the body than real acupuncture.

Participants needed: 78
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 21, 2026Locations: 1
Eligibility criteria

Age 18 or older [+1]

The study Principal Investigator will review the medical record again prior to e... [+4]

Status: Recruiting

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.

Participants needed: 50
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 21, 2026Locations: 1
Eligibility criteria

≥ 18 years of age on the day of signing informed consent. [+13]

Has a history of CMV end-organ disease or CS-CMVi within 6 months prior to enrol... [+10]

Status: Recruiting

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.

Participants needed: 2,700
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 21, 2026Locations: 4
Eligibility criteria

18 years of age or older [+3]

Transfer to an acute care hospital [+8]

Status: Recruiting

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.

Participants needed: 67
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 17, 2026Locations: 1
Eligibility criteria

Subjects ≥ 18 years at the first screening examination/visit. [+13]

Patients with cancers with known driver mutations for which there are known and... [+10]

Status: Recruiting

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).

Participants needed: 102
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: University of California, IrvineUpdated: Jul 17, 2026Locations: 1
Eligibility criteria

Histologic or pathologic diagnosis of stage III-IV epithelial ovarian, fallopian... [+11]

Prior history of any cancer (other than non-melanoma skin cancer) [+11]

Status: Recruiting

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.

Participants needed: 44
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 14, 2026Locations: 2
Eligibility criteria

Male and female subjects aged 18-65 years [+6]

Hiatal hernia >2cm (defined as maximum axial height from end of the esophagus to... [+19]

Status: Recruiting

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.

Participants needed: 75
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 14, 2026Locations: 1
Eligibility criteria

Cohort-specific inclusion for male and female patients. [+12]

Cohort A (no prior cranial radiation) [+9]

Status: Recruiting

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Participants needed: 15
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to pr... [+2]

Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resect... [+2]

Status: Recruiting

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Participants needed: 12
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 10, 2026Locations: 2
Eligibility criteria

Participants must be greater than 18 years of age. [+7]

Individuals currently receiving or received Reiki treatment in the past 30 days [+2]

Status: Recruiting

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

This is a proof of principle clinical trial determining efficacy of single dose dualimmune checkpoint inhibitors to increase intra-tumoral T cells in esophageal, gastroesophageal junction, and gastric adenocarcinomas. These are subjects who have not previously been treated for their disease, who are willing to undergo biopsy procedures, who's disease has not spread to other parts of the body, who's tumors have ARID1A mutations.

Participants needed: 34
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 7, 2026Locations: 1
Eligibility criteria

Non metastatic GEC including locally advanced unresectable [+8]

Patients with known metastatic disease [+3]

Status: Recruiting

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.

Participants needed: 35
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 1, 2026Locations: 1
Eligibility criteria

Histologic or radiographic diagnosis of hepatocellular carcinoma [+21]

Any type of previous systemic anti-cancer treatment [+43]

Status: Recruiting

The Effects of Core Shamanism in Fibromyalgia

This study aims to determine the feasibility of a shamanism intervention for patients with fibromyalgia, acquire efficacy data to determine if Shamanism reduces clinical pain and other common symptoms associated with fibromyalgia, and determine if the Shamanism intervention changes heart rate electrocardiogram (ECG), breathing rate, and brain wave electroencephalogram (EEG) outcomes in fibromyalgia patients and shamanic practitioners. The investigators hypothesize that 80% of individuals will complete at least 80% of study visits, clinical pain severity and/or interference will be significantly reduced following the Shamanic intervention, and lung, heart, and/or brain activity will be altered with the Shamanic intervention and also become more synchronized between Shamanic Practitioners (SPs) and patients during the course of treatment.

Participants needed: 25
Trial details
Age: 18-75Biological sex: FemaleType: InterventionalSponsor: University of California, IrvineUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Female [+8]

Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid a... [+17]

Status: Recruiting

Treatment of Meniere's Disease With Migraine Medications

Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.

Participants needed: 40
Trial details
Phase: Phase 4Age: 25-85Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 22, 2026Locations: 1
Eligibility criteria

Patients with active or frequent Meniere's Disease. [+3]

Pregnancy will result in automatic exclusion from the study. A urine pregnancy t... [+6]

Status: Recruiting

Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture

This study aims to see whether acupuncture can help fibromyalgia patients by giving them acupuncture treatment and seeing whether acupuncture helps enhance the effects of an opioid.

Participants needed: 45
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 15, 2026Locations: 1
Eligibility criteria

Are 18 - 80 years old [+3]

Are younger than 18 or older than 80 years old [+5]

Status: Recruiting

Acoustic and Electrical Stimulation for the Treatment of Tinnitus

Tinnitus, or ringing in the ears, affects 10% to 30% of the population. Of those, 20% have tinnitus bothersome enough to seek medical attention. In many people, tinnitus can significantly affect the quality of life. At this point in time, there is no effective treatment or cure available for tinnitus. It has been found that electrical stimulation of the inner ear can reduce and in some cases eliminate tinnitus. The purpose of this research is to investigate both acoustic and electrical stimulation of the inner ear as a possible treatment of tinnitus. In both acoustic and electrical testing conditions, the subjects will be instructed to be familiar with a 0-10 ranking scale of loudness. In acoustic testing, the stimulus will be presented through headphones in a noiseless environment, and the subject will be asked to report on the loudness of the presented sound and the level of the tinnitus at 20-second intervals. If the subject cannot perceive the presence of the tinnitus, a value of zero will be assigned. A typical sound will be presented for 3 to 6 minutes. Loudness will be reported for 1 to 4 minutes after stimulus offset to measure the presence and duration of residual inhibition. Electrical stimulation will be delivered to the inner ear in three ways, 1. using a cochlear implant (implant placed in the inner ear to replace hearing function), 2. Using an electrode placed in the ear canal, and 3. using a small needle inserted through the ear drum. Various electrical signals will be used to evaluate the reduction in the tinnitus perception by the subject. The subjects will rate the loudness of the tinnitus before, during, and after the electrical signal. Surveys will be used to evaluate the tinnitus loudness and the quality of life of the subjects. Hearing tests will be used before and after the procedures. The long term goal of this research is to develop a device to treat tinnitus in people who can hear and to develop programs for cochlear implants that help treat tinnitus in deaf people.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 11, 2026Locations: 1
Eligibility criteria

18 years or older [+4]

Aged less than 18 years [+7]

Status: Recruiting

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.

Participants needed: 120
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 9, 2026Locations: 1
Eligibility criteria

Male and female subjects aged 18-70 years [+5]

Type 1 diabetes [+32]

Status: Not yet recruiting

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.

Participants needed: 35
Trial details
Phase: Phase 2Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 5, 2026Locations: 1
Eligibility criteria

≥18 years at the time of signing informed consent form (ICF) and able to indepen... [+15]

Participants with visceral, bone, or brain metastases. [+19]

Status: Not yet recruiting

Chatbot for Online Support Groups to Treat Tobacco Addiction

Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. Participants will be randomized to an intervention arm (chatbot-enhanced support group), or a control arm (support group only). In the intervention arm (N=60), each support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). The intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so. In the control arm (N=60), the support groups will be connected to an automated message-posting bot running on a secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot. But both the intelligent chatbot and the automated message-posting bot will post a pre-written daily discussion topic to encourage participants to discuss issues known to facilitate tobacco cessation or group bonding.

Participants needed: 120
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 22, 2026
Eligibility criteria

Cigarette smokers (can also use e-cigarettes) [+10]

No NRT health contraindications [+3]

Status: Recruiting

Mapping Ibogaine Neural Dynamics in Opioid Use Disorder

This study aims to understand how ibogaine treatment may change brain activity and symptoms in people with moderate-severe opioid use disorder (OUD), as defined by the DSM-5. Ibogaine is a plant-derived compound that some studies suggest can reduce opioid cravings and withdrawal. Participants in this study will already be independently scheduled to receive legal ibogaine treatment at a licensed clinic outside of the U.S. The University of California, Irvine (UCI) research team will not provide the treatment but will conduct brain imaging, administer psychometric questionnaires, and obtain urine samples throughout the course of this study. UCI does not sponsor or financially support the ibogaine treatment in any way; all treatment costs are the sole responsibility of the participant. The main goal is to see if ibogaine changes brain function as assessed with magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electroencephalography (EEG). MRI/MRS will measure brain activity when participants view opioid-related images, brain connectivity at rest, and levels of brain chemicals involved in craving and substance use. EEG will measure brain wave activity. MRI/MRS/EEG will be administered across 3 study time points. In addition, participants will complete psychometric surveys related to opioid craving, withdrawal symptoms, mood, anxiety, pain, and quality of life, along with urine tests to monitor substance use and screen for pregnancy. The investigators hypothesize that after ibogaine treatment, participants will show reduced brain responses to opioid cues, changes in brain connectivity and chemistry, and improvements in self-reported cravings and other symptoms. This information may help researchers better understand how ibogaine works in the brain and whether it could play a role in future treatments for OUD.

Participants needed: 20
Trial details
Age: 21-70Biological sex: AllType: ObservationalSponsor: University of California, IrvineUpdated: May 18, 2026Locations: 1
Eligibility criteria

Adults aged 21-70 with confirmed moderate to severe OUD as assessed by equal or... [+7]

Presence of known past procedures, devices in the body, claustrophobia, or other... [+8]